<?xml version='1.0' encoding='utf-8'?>
<document id="27530469"><sentence text="Managing drug-drug interactions with new direct-acting antiviral agents in chronic hepatitis C." /><sentence text="Several direct-acting antiviral agents (DAAs) have marketing authorization in Europe and in the USA and have changed the landscape of hepatitis C treatment: each DAA has its own metabolism and drug-drug interactions (DDIs), and managing them is a challenge" /><sentence text=" To compile the pharmacokinetics and DDI data of the new DAA and to provide a guide for management of DDI" /><sentence text=" An indexed MEDLINE search was conducted using the keywords: DAA, hepatitis C, simeprevir, daclatasvir, ledipasvir, sofosbuvir, 3D regimen (paritaprevir/ritonavir, ombitasvir, dasabuvir), DDI and pharmacokinetics"><entity charOffset="79-89" id="DDI-PubMed.27530469.s4.e0" text="simeprevir" /><entity charOffset="91-102" id="DDI-PubMed.27530469.s4.e1" text="daclatasvir" /><entity charOffset="104-114" id="DDI-PubMed.27530469.s4.e2" text="ledipasvir" /><entity charOffset="116-126" id="DDI-PubMed.27530469.s4.e3" text="sofosbuvir" /><entity charOffset="140-152" id="DDI-PubMed.27530469.s4.e4" text="paritaprevir" /><entity charOffset="153-162" id="DDI-PubMed.27530469.s4.e5" text="ritonavir" /><entity charOffset="164-174" id="DDI-PubMed.27530469.s4.e6" text="ombitasvir" /><entity charOffset="176-185" id="DDI-PubMed.27530469.s4.e7" text="dasabuvir" /><entity charOffset="188-191" id="DDI-PubMed.27530469.s4.e8" text="DDI" /><pair ddi="false" e1="DDI-PubMed.27530469.s4.e0" e2="DDI-PubMed.27530469.s4.e0" /><pair ddi="false" e1="DDI-PubMed.27530469.s4.e0" e2="DDI-PubMed.27530469.s4.e1" /><pair ddi="false" e1="DDI-PubMed.27530469.s4.e0" e2="DDI-PubMed.27530469.s4.e2" /><pair ddi="false" e1="DDI-PubMed.27530469.s4.e0" e2="DDI-PubMed.27530469.s4.e3" /><pair ddi="false" e1="DDI-PubMed.27530469.s4.e0" e2="DDI-PubMed.27530469.s4.e4" /><pair ddi="false" e1="DDI-PubMed.27530469.s4.e0" e2="DDI-PubMed.27530469.s4.e5" /><pair ddi="false" e1="DDI-PubMed.27530469.s4.e0" e2="DDI-PubMed.27530469.s4.e6" /><pair ddi="false" e1="DDI-PubMed.27530469.s4.e0" e2="DDI-PubMed.27530469.s4.e7" /><pair ddi="false" e1="DDI-PubMed.27530469.s4.e0" e2="DDI-PubMed.27530469.s4.e8" /><pair ddi="false" e1="DDI-PubMed.27530469.s4.e1" e2="DDI-PubMed.27530469.s4.e1" /><pair ddi="false" e1="DDI-PubMed.27530469.s4.e1" e2="DDI-PubMed.27530469.s4.e2" /><pair ddi="false" e1="DDI-PubMed.27530469.s4.e1" e2="DDI-PubMed.27530469.s4.e3" /><pair ddi="false" e1="DDI-PubMed.27530469.s4.e1" e2="DDI-PubMed.27530469.s4.e4" /><pair ddi="false" e1="DDI-PubMed.27530469.s4.e1" e2="DDI-PubMed.27530469.s4.e5" /><pair ddi="false" e1="DDI-PubMed.27530469.s4.e1" e2="DDI-PubMed.27530469.s4.e6" /><pair ddi="false" e1="DDI-PubMed.27530469.s4.e1" e2="DDI-PubMed.27530469.s4.e7" /><pair ddi="false" e1="DDI-PubMed.27530469.s4.e1" e2="DDI-PubMed.27530469.s4.e8" /><pair ddi="false" e1="DDI-PubMed.27530469.s4.e2" e2="DDI-PubMed.27530469.s4.e2" /><pair ddi="false" e1="DDI-PubMed.27530469.s4.e2" e2="DDI-PubMed.27530469.s4.e3" /><pair ddi="false" e1="DDI-PubMed.27530469.s4.e2" e2="DDI-PubMed.27530469.s4.e4" /><pair ddi="false" e1="DDI-PubMed.27530469.s4.e2" e2="DDI-PubMed.27530469.s4.e5" /><pair ddi="false" e1="DDI-PubMed.27530469.s4.e2" e2="DDI-PubMed.27530469.s4.e6" /><pair ddi="false" e1="DDI-PubMed.27530469.s4.e2" e2="DDI-PubMed.27530469.s4.e7" /><pair ddi="false" e1="DDI-PubMed.27530469.s4.e2" e2="DDI-PubMed.27530469.s4.e8" /><pair ddi="false" e1="DDI-PubMed.27530469.s4.e3" e2="DDI-PubMed.27530469.s4.e3" /><pair ddi="false" e1="DDI-PubMed.27530469.s4.e3" e2="DDI-PubMed.27530469.s4.e4" /><pair ddi="false" e1="DDI-PubMed.27530469.s4.e3" e2="DDI-PubMed.27530469.s4.e5" /><pair ddi="false" e1="DDI-PubMed.27530469.s4.e3" e2="DDI-PubMed.27530469.s4.e6" /><pair ddi="false" e1="DDI-PubMed.27530469.s4.e3" e2="DDI-PubMed.27530469.s4.e7" /><pair ddi="false" e1="DDI-PubMed.27530469.s4.e3" e2="DDI-PubMed.27530469.s4.e8" /><pair ddi="false" e1="DDI-PubMed.27530469.s4.e4" e2="DDI-PubMed.27530469.s4.e4" /><pair ddi="false" e1="DDI-PubMed.27530469.s4.e4" e2="DDI-PubMed.27530469.s4.e5" /><pair ddi="false" e1="DDI-PubMed.27530469.s4.e4" e2="DDI-PubMed.27530469.s4.e6" /><pair ddi="false" e1="DDI-PubMed.27530469.s4.e4" e2="DDI-PubMed.27530469.s4.e7" /><pair ddi="false" e1="DDI-PubMed.27530469.s4.e4" e2="DDI-PubMed.27530469.s4.e8" /><pair ddi="false" e1="DDI-PubMed.27530469.s4.e5" e2="DDI-PubMed.27530469.s4.e5" /><pair ddi="false" e1="DDI-PubMed.27530469.s4.e5" e2="DDI-PubMed.27530469.s4.e6" /><pair ddi="false" e1="DDI-PubMed.27530469.s4.e5" e2="DDI-PubMed.27530469.s4.e7" /><pair ddi="false" e1="DDI-PubMed.27530469.s4.e5" e2="DDI-PubMed.27530469.s4.e8" /><pair ddi="false" e1="DDI-PubMed.27530469.s4.e6" e2="DDI-PubMed.27530469.s4.e6" /><pair ddi="false" e1="DDI-PubMed.27530469.s4.e6" e2="DDI-PubMed.27530469.s4.e7" /><pair ddi="false" e1="DDI-PubMed.27530469.s4.e6" e2="DDI-PubMed.27530469.s4.e8" /><pair ddi="false" e1="DDI-PubMed.27530469.s4.e7" e2="DDI-PubMed.27530469.s4.e7" /><pair ddi="false" e1="DDI-PubMed.27530469.s4.e7" e2="DDI-PubMed.27530469.s4.e8" /></sentence><sentence text=" Data were also collected from hepatology, and infectious disease and clinical pharmacology conferences abstracts" /><sentence text=" Food can play a role in the absorption of DAAs" /><sentence text=" Most of the interactions are linked to metabolism (cytochrome P450-3Â A4 [CYP3A4]) or hepatic and/or intestinal transporters (organic anion-transporting polypeptide and P-glycoprotein [P-gp])" /><sentence text=" To a lesser extent other pathways can be involved such as breast cancer resistance protein transporter or UDP-glucuronosyltransferase metabolism" /><sentence text=" DDI are more likely to occur with 3D regimen, daclatasvir, simeprevir and ledipasvir, as they are all both substrates and inhibitors of P-gp and/or CYP3A4, than with sofosbuvir"><entity charOffset="47-58" id="DDI-PubMed.27530469.s9.e0" text="daclatasvir" /><entity charOffset="60-70" id="DDI-PubMed.27530469.s9.e1" text="simeprevir" /><entity charOffset="75-85" id="DDI-PubMed.27530469.s9.e2" text="ledipasvir" /><entity charOffset="167-177" id="DDI-PubMed.27530469.s9.e3" text="sofosbuvir" /><entity charOffset="1-10" id="DDI-PubMed.27530469.s9.e4" text="DDI" /><pair ddi="false" e1="DDI-PubMed.27530469.s9.e4" e2="DDI-PubMed.27530469.s9.e4" /><pair ddi="false" e1="DDI-PubMed.27530469.s9.e4" e2="DDI-PubMed.27530469.s9.e0" /><pair ddi="false" e1="DDI-PubMed.27530469.s9.e4" e2="DDI-PubMed.27530469.s9.e1" /><pair ddi="false" e1="DDI-PubMed.27530469.s9.e4" e2="DDI-PubMed.27530469.s9.e2" /><pair ddi="false" e1="DDI-PubMed.27530469.s9.e4" e2="DDI-PubMed.27530469.s9.e3" /><pair ddi="false" e1="DDI-PubMed.27530469.s9.e0" e2="DDI-PubMed.27530469.s9.e0" /><pair ddi="false" e1="DDI-PubMed.27530469.s9.e0" e2="DDI-PubMed.27530469.s9.e1" /><pair ddi="false" e1="DDI-PubMed.27530469.s9.e0" e2="DDI-PubMed.27530469.s9.e2" /><pair ddi="false" e1="DDI-PubMed.27530469.s9.e0" e2="DDI-PubMed.27530469.s9.e3" /><pair ddi="false" e1="DDI-PubMed.27530469.s9.e1" e2="DDI-PubMed.27530469.s9.e1" /><pair ddi="false" e1="DDI-PubMed.27530469.s9.e1" e2="DDI-PubMed.27530469.s9.e2" /><pair ddi="false" e1="DDI-PubMed.27530469.s9.e1" e2="DDI-PubMed.27530469.s9.e3" /><pair ddi="false" e1="DDI-PubMed.27530469.s9.e2" e2="DDI-PubMed.27530469.s9.e2" /><pair ddi="false" e1="DDI-PubMed.27530469.s9.e2" e2="DDI-PubMed.27530469.s9.e3" /></sentence><sentence text=" They can increase concentrations of coadministered drugs and their concentrations may be influenced by P-gp or CYP3A4 inducers or inhibitors" /><sentence text=" Overdosage or low dosage can be encountered with potent inducers or inhibitors of CYP3A4 or drugs with a narrow therapeutic range" /><sentence text=" The key to interpret DDI data is a good understanding of the pharmacokinetic profiles of the drugs involved"><entity charOffset="22-24" id="DDI-PubMed.27530469.s12.e0" text="DDI" /></sentence><sentence text=" Their ability to inhibit CYP450-3A4 and transporters (hepatic and/or intestinal) can have significant clinical consequences" /><sentence text="" /></document>